

AmpliPhi Biosciences Corp  
Form 8-K  
November 06, 2014

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): October 31, 2014**

**AMPLIPHI BIOSCIENCES CORPORATION**

**(Exact name of Registrant as specified in its charter)**

**Washington                      000-23930      91-1549568**  
**(State or other jurisdiction of   (Commission   (I.R.S. Employer**  
**incorporation or organization) File Number) Identification No.)**

**4870 Sadler Road, Suite 300**

**Glen Allen, Virginia 23060**

**(Address of principal executive offices) (Zip code)**

**(804) 205-5069**

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01 Entry into a Material Definitive Agreement.**

On October 31, 2014, the AmpliPhi Biosciences Corporation (the “Company”) amended its employment offer letter, dated October 7, 2013, with Baxter Phillips, III. Pursuant to this amendment, as of October 22, 2014, Mr. Phillips will serve as Chief Business Officer of the Company. His base salary will be \$250,000 per year. If Mr. Phillips continues to be an employee of the Company on June 1, 2015, he will be eligible to receive a \$50,000 bonus to be paid within thirty (30) days of such date.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AmpliPhi Biosciences  
Corporation**

Date: November 6, 2014 By: /s/ David E. Boshier  
David E. Boshier

Chief Financial Officer